Reinhart Partners LLC. Increases Stock Holdings in Lantheus Holdings, Inc. $LNTH

Reinhart Partners LLC. lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.2% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 1,599,379 shares of the medical equipment provider’s stock after acquiring an additional 34,501 shares during the period. Lantheus makes up about 4.1% of Reinhart Partners LLC.’s investment portfolio, making the stock its 2nd largest position. Reinhart Partners LLC.’s holdings in Lantheus were worth $177,437,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Assenagon Asset Management S.A. lifted its stake in Lantheus by 440.3% in the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock valued at $79,320,000 after acquiring an additional 582,661 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Lantheus by 6.4% during the 2nd quarter. GAMMA Investing LLC now owns 3,348 shares of the medical equipment provider’s stock worth $371,000 after purchasing an additional 202 shares during the last quarter. Versant Capital Management Inc raised its holdings in shares of Lantheus by 33.0% in the 2nd quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock valued at $65,000 after purchasing an additional 146 shares during the period. Empowered Funds LLC bought a new stake in shares of Lantheus in the 1st quarter valued at about $909,000. Finally, Carmignac Gestion lifted its stake in Lantheus by 18.4% in the 1st quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider’s stock valued at $100,729,000 after purchasing an additional 206,000 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Citizens Jmp reissued a “market outperform” rating and set a $115.00 price target on shares of Lantheus in a research report on Monday, June 29th. CJS Securities cut Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday. Leerink Partners set a $102.50 target price on Lantheus in a research note on Monday. Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Finally, Weiss Ratings upgraded Lantheus from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 31st. Five investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Lantheus presently has an average rating of “Hold” and a consensus price target of $108.11.

Lantheus Stock Down 0.1%

Shares of LNTH opened at $100.95 on Friday. Lantheus Holdings, Inc. has a 52 week low of $49.67 and a 52 week high of $111.86. The firm has a market cap of $6.57 billion, a P/E ratio of 24.38 and a beta of -0.03. The firm’s 50-day simple moving average is $104.09 and its 200 day simple moving average is $87.98. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.64 and a current ratio of 3.06.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.25. The firm had revenue of $388.18 million for the quarter, compared to analysts’ expectations of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business’s revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.57 EPS. On average, analysts forecast that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.